Anatara Lifesciences Ltd Update on Anti-Obesity Project
Anatara Lifesciences Ltd (ASX: ANR) has shared an update on its Anti-Obesity Project, highlighting encouraging outcomes from pre-clinical studies. The candidate compound, AOC, demonstrated potential in both weight reduction and the prevention of weight regain following the discontinuation of injectable weight loss medications. Specifically, AOC significantly reduced weight gain and perigonadal fat in test mice, indicating its potential for supporting weight loss maintenance.
However, Mechanism of Action (MOA) studies have not conclusively demonstrated a direct effect on endogenous GLP-1 levels. Consequently, Anatara plans to conduct a limited human pharmacokinetic study to further explore AOC’s effects. Although the company remains confident in its financial ability to fund this study, it is considering putting the project on hold to focus on other strategic initiatives, including potential mergers and acquisitions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Anatara Lifesciences Ltd Update on Anti-Obesity Project
Anatara Lifesciences Ltd (ASX: ANR) has shared an update on its Anti-Obesity Project, highlighting encouraging outcomes from pre-clinical studies. The candidate compound, AOC, demonstrated potential in both weight reduction and the prevention of weight regain following the discontinuation of injectable weight loss medications. Specifically, AOC significantly reduced weight gain and perigonadal fat in test mice, indicating its potential for supporting weight loss maintenance.
However, Mechanism of Action (MOA) studies have not conclusively demonstrated a direct effect on endogenous GLP-1 levels. Consequently, Anatara plans to conduct a limited human pharmacokinetic study to further explore AOC’s effects. Although the company remains confident in its financial ability to fund this study, it is considering putting the project on hold to focus on other strategic initiatives, including potential mergers and acquisitions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au